Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spero Therapeutics (SPRO) EBT (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed EBT for 10 consecutive years, with -$6.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT rose 60.66% year-over-year to -$6.8 million, compared with a TTM value of -$43.1 million through Sep 2025, down 1282.94%, and an annual FY2024 reading of -$68.6 million, down 369.99% over the prior year.
  • EBT was -$6.8 million for Q3 2025 at Spero Therapeutics, down from -$1.7 million in the prior quarter.
  • Across five years, EBT topped out at $51.6 million in Q4 2023 and bottomed at -$30.1 million in Q1 2022.
  • Average EBT over 5 years is -$10.4 million, with a median of -$13.9 million recorded in 2025.
  • The sharpest move saw EBT soared 181.17% in 2022, then crashed 39470.45% in 2024.
  • Year by year, EBT stood at -$27.4 million in 2021, then skyrocketed by 181.17% to $22.3 million in 2022, then surged by 131.67% to $51.6 million in 2023, then crashed by 140.13% to -$20.7 million in 2024, then surged by 66.9% to -$6.8 million in 2025.
  • Business Quant data shows EBT for SPRO at -$6.8 million in Q3 2025, -$1.7 million in Q2 2025, and -$13.9 million in Q1 2025.